Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group

Bo Shen¹, Gursimran S Kochhar², Udayakumar Navaneethan³, Raymond K Cross⁴, Francis A Farraye⁵, Marietta Iacucci⁶, David A Schwartz⁷, Yago Gonzalez-Lama⁸, Jason Schairer⁹, Ravi P Kiran¹⁰, Paulo Gustavo Kotze¹¹, Taku Kobayashi¹², Martin Bortlik¹³, Xiuli Liu¹⁴, Alexander N Levy¹⁵, Begoña González Suárez¹⁶, Shou-Jiang Tang¹⁷, Nayantara Coelho-Prabhu¹⁸, Martin Lukas¹⁹, David H Bruining¹⁸, Sandra El-Hachem², Roger J Charles²⁰, Yan Chen²¹, Ajit Sood²², Ren Mao²³, Carme Loras²⁴, Parambir S Dulai²⁵, Joseph A Picoraro²⁶, Michael Chiorean²⁷, Milan Lukas²⁸, Amandeep Shergill²⁹, Mark S Silverberg³⁰, William J Sandborn²⁵, Charles N Bernstein³¹

Affiliations

¹ Center for Interventional Inflammatory Bowel Disease, Columbia University Irving Medical Center, New York Presbyterian Hospital, NY, USA. Electronic address: bs3270@cumc.columbia.edu.
² Division of Gastroenterology, Hepatology, and Nutrition, Allegheny Health Network, Pittsburgh, PA, USA.
³ IBD Center and IBD Interventional Unit, Digestive Health Institute, Orlando Health, Orlando, FL, USA.
⁴ Inflammatory Bowel Disease Program, University of Maryland School of Medicine, Maryland, MD, USA.
⁵ Department of Gastroenterology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
⁶ Institute of Immunology and Immunotherapy, NIHR Birmingham Biomedical Research Centre, University Hospitals NHS Foundation Trust, University of Birmingham, UK.
⁷ Department of Gastroenterology, Vanderbilt University Medical Center, Nashville, TN, USA.
⁸ IBD Unit, Gastroenterology and Hepatology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
⁹ Department of Gastroenterology, Henry Ford Hospital, Detroit, MI, USA.
¹⁰ Division of Colorectal Surgery, Columbia University Irving Medical Center, New York Presbyterian Hospital, NY, USA.
¹¹ IBD Outpatients Clinic, Catholic University of Paraná, Curitiba, Brazil.
¹² Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
¹³ Department of Gastroenterology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic.
¹⁴ Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainsville, FL, USA.
¹⁵ Division of Gastroenterology and Hepatology, Tufts Medical Center, Boston, MA, USA.
¹⁶ Gastroenterology Department, Instituto Clínic de Enfermedades Digestivas y Metabólicas, Hospital Clínic de Barcelona, Barcelona, Spain.
¹⁷ Division of Gastroenterology, University of Mississippi Medical Center, Jackson, MS, USA.
¹⁸ Department of Gastroenterology, Mayo Clinic, Rochester, MN, USA.
¹⁹ Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE Clinical Centre, Prague, Czech Republic.
²⁰ Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, FL, USA.
²¹ Center for Inflammatory Bowel Disease, Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
²² Department of Gastroenterology, Dayanand Medical College & Hospital, Ludhiāna, Punjab, India.
²³ Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
²⁴ Department of Gastroenterology, Hospital Universitari Mútua Terrassa, Fundació per la Recerca Mútua Terrassa, Terrassa, Catalonia; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.
²⁵ Department of Gastroenterology, University of California San Diego, San Diego, CA, USA.
²⁶ Division of Pediatric Gastroenterology, Columbia University Irving Medical Center, New York Presbyterian Hospital, NY, USA.
²⁷ Center for Inflammatory Bowel Disease, Virginia Mason Clinic, Seattle, WA, USA.
²⁸ Clinical and Research Centre for Inflammatory Bowel Disease, Clinical Centre ISCARE, Prague, Czech Republic.
²⁹ San Francisco Veterans Affairs Medical Center and Department of Gastroenterology, University of California, San Francisco, CA, USA.
³⁰ Mount Sinai Hospital Inflammatory Bowel Disease Centre, Toronto, ON, Canada.
³¹ Inflammatory Bowel Disease Clinical and Research Centre, University of Manitoba, Winnipeg, MB, Canada.

PMID: 33872568
DOI: 10.1016/S2468-1253(20)30394-0

Review

Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group

Bo Shen et al. Lancet Gastroenterol Hepatol. 2021 Jun.

. 2021 Jun;6(6):482-497.

doi: 10.1016/S2468-1253(20)30394-0. Epub 2021 Apr 17.

Authors

Affiliations

¹ Center for Interventional Inflammatory Bowel Disease, Columbia University Irving Medical Center, New York Presbyterian Hospital, NY, USA. Electronic address: bs3270@cumc.columbia.edu.
² Division of Gastroenterology, Hepatology, and Nutrition, Allegheny Health Network, Pittsburgh, PA, USA.
³ IBD Center and IBD Interventional Unit, Digestive Health Institute, Orlando Health, Orlando, FL, USA.
⁴ Inflammatory Bowel Disease Program, University of Maryland School of Medicine, Maryland, MD, USA.
⁵ Department of Gastroenterology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
⁶ Institute of Immunology and Immunotherapy, NIHR Birmingham Biomedical Research Centre, University Hospitals NHS Foundation Trust, University of Birmingham, UK.
⁷ Department of Gastroenterology, Vanderbilt University Medical Center, Nashville, TN, USA.
⁸ IBD Unit, Gastroenterology and Hepatology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
⁹ Department of Gastroenterology, Henry Ford Hospital, Detroit, MI, USA.
¹⁰ Division of Colorectal Surgery, Columbia University Irving Medical Center, New York Presbyterian Hospital, NY, USA.
¹¹ IBD Outpatients Clinic, Catholic University of Paraná, Curitiba, Brazil.
¹² Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
¹³ Department of Gastroenterology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic.
¹⁴ Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainsville, FL, USA.
¹⁵ Division of Gastroenterology and Hepatology, Tufts Medical Center, Boston, MA, USA.
¹⁶ Gastroenterology Department, Instituto Clínic de Enfermedades Digestivas y Metabólicas, Hospital Clínic de Barcelona, Barcelona, Spain.
¹⁷ Division of Gastroenterology, University of Mississippi Medical Center, Jackson, MS, USA.
¹⁸ Department of Gastroenterology, Mayo Clinic, Rochester, MN, USA.
¹⁹ Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE Clinical Centre, Prague, Czech Republic.
²⁰ Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, FL, USA.
²¹ Center for Inflammatory Bowel Disease, Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
²² Department of Gastroenterology, Dayanand Medical College & Hospital, Ludhiāna, Punjab, India.
²³ Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
²⁴ Department of Gastroenterology, Hospital Universitari Mútua Terrassa, Fundació per la Recerca Mútua Terrassa, Terrassa, Catalonia; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.
²⁵ Department of Gastroenterology, University of California San Diego, San Diego, CA, USA.
²⁶ Division of Pediatric Gastroenterology, Columbia University Irving Medical Center, New York Presbyterian Hospital, NY, USA.
²⁷ Center for Inflammatory Bowel Disease, Virginia Mason Clinic, Seattle, WA, USA.
²⁸ Clinical and Research Centre for Inflammatory Bowel Disease, Clinical Centre ISCARE, Prague, Czech Republic.
²⁹ San Francisco Veterans Affairs Medical Center and Department of Gastroenterology, University of California, San Francisco, CA, USA.
³⁰ Mount Sinai Hospital Inflammatory Bowel Disease Centre, Toronto, ON, Canada.
³¹ Inflammatory Bowel Disease Clinical and Research Centre, University of Manitoba, Winnipeg, MB, Canada.

PMID: 33872568
DOI: 10.1016/S2468-1253(20)30394-0

Erratum in

Correction to Lancet Gastroenterol Hepatol 2021; 6: 482-97.
[No authors listed] [No authors listed] Lancet Gastroenterol Hepatol. 2021 Jun;6(6):e5. doi: 10.1016/S2468-1253(21)00144-8. Lancet Gastroenterol Hepatol. 2021. PMID: 34015357 No abstract available.

Abstract

The majority of patients with Crohn's disease and a proportion of patients with ulcerative colitis will ultimately require surgical treatment despite advances in diagnosis, therapy, and endoscopic interventions. The surgical procedures that are most commonly done include bowel resection with anastomosis, strictureplasty, faecal diversion, and ileal pouch. These surgical treatment modalities result in substantial alterations in bowel anatomy. In patients with inflammatory bowel disease, endoscopy plays a key role in the assessment of disease activity, disease recurrence, treatment response, dysplasia surveillance, and delivery of endoscopic therapy. Endoscopic evaluation and management of surgically altered bowel can be challenging. This consensus guideline delineates anatomical landmarks and endoscopic assessment of these landmarks in diseased and surgically altered bowel.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests CNB reports grants and personal fees from AbbVie, Janssen Canada, Pfizer Canada, and Takeda Canada, and personal fees from Roche Canada, Bristol Myers Squibb Canada, Sandoz Canada, Mylan Pharmaceuticals, Takeda, and Medtronics Canada. DHB reports grants from Medtronic. JS reports personal fees from Takeda and Pfizer. PGK reports grants and personal fees from Pfizer and Takeda, and personal fees from AbbVie and Jansen. UN reports grants and personal fees from Takeda, Janssen, and AbbVie, and personal fees from Pfizer. RKC reports personal fees from AbbVie, Janssen, Pfizer, Samsung Bioepis, and Takeda. WJS reports grants, personal fees, and stock or stock options from Prometheus Biosciences; grants and personal fees from AbbVie, Abivax, Alimentiv, Arena Pharmaceuticals, Boehringer-Ingelheim, Celgene, Genentech (Roche), Gilead Sciences, Glaxo Smith Kline, Janssen, Lilly, Pfizer, Seres Therapeutics, Shire, Surrozen, Takeda, and Theravance Biopharma; personal fees and stock or stock options from Beigene, Gossamer Bio, Oppilan Pharma, Progenity, Shoreline Bioscience, and Vivreon Biosciences; grants and stock options from Allakos; personal fees from Alivio Therapeutics, Admirx, Alfasigma, Allergan, Amgen, Applied Molecular Transport, Avexegen Therapeutics, Bausch Health (Salix), Bellatrix Pharmaceuticals, Boston Pharmaceuticals, Bristol Meyer Squibb, Celltrion, Cellularity, Conatus, Cosmo Pharmaceuticals, Escalier Biosciences, Ferring, Forbion, Equillium, Glanmark Pharmaceuticals, Immunic (Vital Therapies), Incyte, Index Pharmaceuticals, Intact Therapeutics, Kyowa Kirin Pharmaceutical Research, Kyverna Therapeutics, Landos Biopharma, Miraca Life Sciences, Nivalis Therapeutics, Novartis, Nutrition Science Partners, Otsuka, Pandion Therapeutics, Paul Hastings, Protagonist Therapeutics, Provention Bio, Reistone Biopharma, Ritter Pharmaceuticals, Shanghai Pharma Biotherapeutics, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Thetis Pharmaceuticals, Tigenix, Tillots Pharma, UCB Pharma, Vendata Biosciences, Vivelix Pharmaceuticals, and Zealand Pharma; and stock or stock options from Ventyx Biosciences and Vimalan Biosciences. MSS reports grants and personal fees from Janssen, AbbVie, Takeda, and Pfizer, and grants from Prometheus. All other authors declare no competing interests.

Comment in

Endoscopic evaluation after surgery in inflammatory bowel disease.
Syal G, Fleshner PR, Melmed GY. Syal G, et al. Lancet Gastroenterol Hepatol. 2021 Sep;6(9):690-691. doi: 10.1016/S2468-1253(21)00225-9. Lancet Gastroenterol Hepatol. 2021. PMID: 34391521 No abstract available.
Endoscopic evaluation after surgery in inflammatory bowel disease - Authors' reply.
Shen B, Bortlik M, Bruining DH, Coelho-Prabhu N, El-Hachem S, Farraye FA, Iacucci M, Kobayashi T, Kochhar GS, Kotze PG, Lama YG, Levy AN, Liu X, Mao R, Navaneethan U, Schwartz DA, Shergill A, Sood A, Suárez BG. Shen B, et al. Lancet Gastroenterol Hepatol. 2021 Sep;6(9):691-692. doi: 10.1016/S2468-1253(21)00255-7. Lancet Gastroenterol Hepatol. 2021. PMID: 34391522 No abstract available.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group

Affiliations

Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

Comment in

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical